Read by QxMD icon Read


Mario Alvarez-Maestro, Juan Gómez Rivas, Alfredo Aguilera Bazán, Luis Martínez-Piñeiro, Alvaro Juarez Soto, Jose Manuel Cozar Olmo, Manuel Esteban Fuertes
Urology is a medical-surgical specialty that deals with the study, diagnosis and treatment of the medical and surgical diseases of the urinary apparatus and retroperitoneum in both sexes and the male genital apparatus without age limit, due to congenital, traumatic, septic, metabolic, obstructive and oncological conditions. Urologic oncology is the broadest urological part, where research and new advances make continuous learning essential. In this chapter we treat all academic features related with training in the field of Urooncology...
January 2018: Archivos Españoles de Urología
Ilker Tinay, Güven Aslan, Ali Riza Kural, Haluk Özen, Bülent Akdoğan, Asıf Yıldırım, Şakir Ongün, Alp Özkan, Tarik Esen, Ferruh Zorlu, Özdal Dillioğlugil, Nural Bekiroglu, Levent Türkeri
INTRODUCTION: To evaluate the pathological outcomes of Turkish men meeting the criteria for Active Surveillance (AS), who elected to undergo immediate radical prostatectomy (RP). MATERIAL AND METHODS: Retrospective analysis including 1,212 patients with clinically localized prostate cancer (PCa) who met the eligibility criteria for AS. The primary outcomes were pathological upstaging and pathological upgrading. RESULTS: Nine hundred ninety-one patients were eligible for analysis after the central review of the submitted data...
2018: Urologia Internationalis
Friederike Haidl, David Pfister, Axel Heidenreich, Isabel Heidegger
The use of antiangiogenic agents in cancer therapy has become an attractive target in oncological research. However, concerning the uro-oncological field, current guidelines only recommend the use of antiangiogenic agents in metastatic renal cell cancer. Yet in recent years, several approaches for sequential treatment with angiogenesis inhibitors in other urogenital malignancies apart from renal cell cancer are ongoing. Thus, the present review article aims to provide an overview about clinical studies with antiangiogenic agents in prostate-, bladder-, testicular-, as well as penile cancer patients...
2017: Memo
J Konert
The term chemotherapy is more than 100 years old and during this period it has been going through decisive changes in terminology. Initially describing an antibacterial therapy it now is known as a part of the new oncologic therapy. Those upheavels and their causes are represented. Conclusively, the evolution of the urooncologic chemotherapy is briefly outlined.
November 2017: Der Urologe. Ausg. A
Can Öbek, Tünkut Doğanca, Emre Demirci, Meltem Ocak, Ali Rıza Kural, Asıf Yıldırım, Uğur Yücetaş, Çetin Demirdağ, Sarper M Erdoğan, Levent Kabasakal
PURPOSE: To assess the diagnostic accuracy of68 Ga-PSMA PET in predicting lymph node (LN) metastases in primary N staging in high-risk and very high-risk nonmetastatic prostate cancer in comparison with morphological imaging. METHODS: This was a multicentre trial of the Society of Urologic Oncology in Turkey in conjunction with the Nuclear Medicine Department of Cerrahpasa School of Medicine, Istanbul University. Patients were accrued from eight centres. Patients with high-risk and very high-risk disease scheduled to undergo surgical treatment with extended LN dissection between July 2014 and October 2015 were included...
October 2017: European Journal of Nuclear Medicine and Molecular Imaging
Franziska Erlmeier, Sandra Steffens, Arndt Hartmann
Immunotherapy with programmed cell death protein-1 (PD-1) antibodies (pembrolizumab and nivolumab) has been approved in Europe for the first-line treatment of several tumour entities, e. g. malignant melanoma. Following the resounding therapeutic success of these antibodies in different types of tumours, their potential in urological tumours has been investigated in several studies. The approval of the PD-1 antibody nivolumab for the treatment of metastasised renal cell carcinoma has set a new milestone in urooncology...
August 2017: Aktuelle Urologie
Oktay Üçer, Ali Can Albaz, Elif Atag, Aziz Karaoglu, Talha Muezzinoglu
PURPOSE: To investigate the proportion of neoadjuvant chemotherapy (NAC) use in patients with muscle invasive bladder cancer before radical cystectomy and the approach of urologists to this subject. MATERIALS AND METHODS: We invited 242 urologists during the 12th International Urooncology Congress in Turkey to answer a self-administered questionnaire. The questionnaire included questions related to radical cystectomy, lymph node dissection and neoadjuvant chemotherapy that had been performed in patients with muscle invasive bladder cancer by the urologist...
October 10, 2016: Urology Journal
D-H Zermann, W Hoffmann, W Vahlensieck
The primary objectives of modern urooncological treatment concepts are quality of life, reintegration and participation. Urological rehabilitation supports the overcoming of side effects of disease and treatment, which is necessary for the timely return to work life. Social medical assessment reflects the individual overall results of the entire treatment process concerning oncological prognosis, physical and mental capacity and resilience.
January 2017: Der Urologe. Ausg. A
Ramazan Kocaaslan, Yunus Kayalı, Adem Tok, Abdulkadir Tepeler
OBJECTIVE: To analyze the publication rates of full-text journal articles converted from the abstracts presented in the 22(nd) Turkish National Urology Congress in 2012. MATERIAL AND METHODS: A total of 576 abstracts accepted for presentation at the 22(nd) Turkish National Urology Association Meeting were identified from the published abstract book. The abstracts were categorized into subsections such as endourology and pediatric urology. The subsequent publication rate for the studies was evaluated by scanning PubMed Medline...
March 2016: Turkish Journal of Urology
L Skrobek, M Boegemann, A Hegele
What new developments in urooncology were discussed at the 2015 annual meetings of ASCO, EAU, DGU and ESMO? This review summarises news relevant to the daily diagnosis and treatment of prostate, bladder and kidney cancer. While study results seem to change paradigms in the treatment of prostate cancer, particularly in metastatic but still hormone-sensitive stages, immunotherapeutic strategies for the treatment of kidney and urothelial cancer are very promising and might expand the systemic therapeutic options in the years to come...
February 2016: Aktuelle Urologie
T Maurer, H Kübler, J E Gschwend, M Eiber
No abstract text is available yet for this article.
September 2015: Der Urologe. Ausg. A
T Maurer, H Kübler, J E Gschwend, M Eiber
The use of positron emission tomography (PET) is an established method for the diagnosis of urological malignancies. Several tracers are currently available to obtain metabolic information or directly detect molecular targets. While (18)F-FDG-PET is recognized in current guidelines for the staging of seminoma, PET is not used in clinical routine in renal malignancies due to the lack of specific tracers. Despite initial promising results in bladder cancer, no relevant additional diagnostic value with PET using (18)F-FDG or choline-based tracers could be obtained in most patients and therefore should be used with caution or only within clinical trials...
July 2015: Der Urologe. Ausg. A
Kirsten Bouchelouche, Peter L Choyke
Imaging plays an important role in the clinical management of cancer patients. Hybrid imaging with PET/computed tomography (CT) is having a broad impact in oncology, and in recent years PET/CT is beginning to have an impact in urooncology. In both bladder and renal cancers, there is a need to study the efficacy of other tracers than F-18 fluorodeoxyglucose (FDG), particularly tracers with limited renal excretion. Thus, new tracers are being introduced. This review focuses on the clinical role of FDG and other PET agents in renal, bladder, and testicular cancers...
July 2015: PET Clinics
A Hegele, L Skrobek, M Boegemann
What is new in urooncology in the year 2014? This review gives a brief but comprehensive overview of new developments in diagnosis and treatment of localized as well as advanced prostate, bladder and kidney cancer which have been presented on the occasion of the annual meetings of the European and American urologic and oncological associations in 2014. Attention is particularly directed to those data and results from trials which might be of direct or indirect clinical relevance.
March 2015: Aktuelle Urologie
Nalan Neşe, Banu S Kumbaraci, Dilek E Baydar, Işin Kiliçaslan, Ayşegül A Sari, Sait Şen, Ipek I Gönül, Duygu Kankaya, Yasemin Özlük, Murat Ermete, Ayşim Özağari, Nebil Bal, Saba Kiremitçi, Kürşat Yildiz, Burçin Tuna, Nilay Şen, Kutsal Yörükoğlu
Small cell carcinoma (SmCC) is a rare and aggressive neuroendocrine carcinoma of the bladder. Neuroendocrine carcinomas expressing somatostatin receptors (SSTR) in other viscera such as lung, pancreas, and gastrointestinal system respond to therapy with somatostatin analogs. In the present study, expressions of SSTRs 1 to 5 including type 2A are investigated by immunohistochemistry (IHC) and their relationship with clinicopathologic factors was evaluated. Hundred primary bladder SmCC cases were collected from 12 centers in Turkey...
April 2016: Applied Immunohistochemistry & Molecular Morphology: AIMM
Osman İnci, Ebru Taştekin, Hakan Gençhellaç, Özcan Arabacı, Serap İşler, İrfan Hüseyin Atakan
BACKGROUND: Urachal masses observed in adults should be considered malignant unless they are confuted. It is very difficult to differentiate between malignant or benign lesions, including especially calcified foci and solid areas. CASE REPORT: Our case was a 63-year-old male patient who was diagnosed as Behçet's Disease 26 years ago. Upon clinical examination, he was also diagnosed with adenocarcinoma of prostate. He was examined by computerized tomography to define the stage of prostatic adenocarcinoma...
January 2015: Balkan Medical Journal
Stênio Cássio Zequi
No abstract text is available yet for this article.
September 2014: International Braz J Urol: Official Journal of the Brazilian Society of Urology
Piotr Zygmunt Wojcieszak, Sławomir Poletajew, Daniel Rutkowski, Piotr Radziszewski
INTRODUCTION: The Polish National Cancer Registry (KRN) is the most commonly used sources of data on the incidence of cancers including renal cancer in Poland. Until today, the accuracy and completeness of these data has never been verified. MATERIAL AND METHODS: The aim of this study was to assess the completeness and reliability of data on the incidence of renal cancer published by the KRN. KRN data on newly diagnosed cases of renal cancer in Poland (for the whole country) and separately in subjectively selected provinces between 2009 and 2011 were retrospectively compared to the data received from the National Health Fund (NFZ) on the number of radical and partial nephrectomies performed due to renal cancer in the same time frame and regions...
2014: Central European Journal of Urology
Levent Turkeri, Naşide Mangir, Bulent Gunlusoy, Asif Yildirim, Sumer Baltaci, Mustafa Kaplan, Murat Bozlu, Aydin Mungan
In patients with microscopic hematuria there is a need for better identification of those who are at greater risk of harbouring bladder tumors. The RisikoCheck® questionnaire has a strong correlation with the presence of urothelial carcinoma (UC) of the bladder and in combination with other available tests may help identify patients who require detailed clinical investigations due to increased risk of presence of bladder tumors. This study aimed to evaluate the efficacy of RisikoCheck® questionnaire together with NMP-22® (BladderChek®) as a point-of-care urine test in predicting the presence of bladder tumors in patients presenting with microscopic hematuria as the sole finding...
2014: Asian Pacific Journal of Cancer Prevention: APJCP
Björn Georgi, Nina Korzeniewski, Boris Hadaschik, Carsten Grüllich, Wilfried Roth, Holger Sültmann, Sascha Pahernik, Markus Hohenfellner, Stefan Duensing
Treatment of castration resistant prostate cancer (CRPC) continues to represent a major urooncological challenge due to tumor heterogeneity and the inevitable development of therapy resistance. Although androgen deprivation therapy retains an important role in the management of CRPC, recent evidence suggests that a broader spectrum of therapeutic targets may improve patient response and delay development of advanced disease. Genome-wide analyses have identified four major signaling nodes that are most frequently altered in prostate cancer: i) the androgen receptor (AR); ii) the PI3K pathway; iii) the Ras/Raf/MEK/ERK pathway; and iv) the retinoblastoma protein (pRB) signaling pathway...
October 2014: International Journal of Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"